跳至主要内容
临床试验/ACTRN12613000138785
ACTRN12613000138785暂停未知

Myeloproliferative Neoplasms Registry: A cancer registration scheme to aid in the planning of health service resources and cancer control programmes and the assessment of their efficacy

Australasian Leukaemia and Lymphoma Group (ALLG)0 个研究点目标入组 300 人开始时间: 2013年2月5日最近更新:
适应症

试验速览

阶段
未知
状态
暂停
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients recently (< 3 months) diagnosed with:
  • Essential Thrombocythaemia (ET)
  • Polycythaemia vera (PV)
  • Primary myelofibrosis (PMF)
  • Myeloproliferative neoplasm- unclassifiable
  • (Exceptions to this will be patients diagnosed with MPNs (PV, ET, PMF, MPN-NOS) at Gosford Hospital, Flinders Medical Centre or Austin Hospital after 1st January 2010, who will be eligible for participation retrospectively)
  • Patients with a new or pre-existing diagnosis of:
  • Chronic eosinophilic leukaemia (CES)
  • Hypereosinophilic syndrome (HES)
  • Refractory anaemia with ring sideroblasts associated with a marked thrombocytosis (RARS-t)
  • Aged 18 and over
  • Written informed consent

排除标准

  • No exclusion criteria

研究者

发起方
Australasian Leukaemia and Lymphoma Group (ALLG)

相似试验